Metformin is a commonly used drug for type 2 diabetes mellitus (T2DM); however, it indirectly activates AMPK, while Tideglusib is a potent, selective and irreversible non-ATP-competitive suppressor of the AMPK inhibitor GSK-3β, with previously established efficacy in animal models and in recent clinical trials for Alzheimer’s disease [40]. Here, PRKAA1 is linked to diabetes mellitus.